Story
Trump's CDC Nominee Erica Schwartz Faces Senate Confirmation Hearing Amid Agency Turmoil

Summary
Erica Schwartz, President Trump's pick to lead the Centers for Disease Control and Prevention, will appear before a Senate panel for her confirmation hearing. The nomination comes as the CDC contends with leadership instability and major public health crises, including a measles resurgence and an Ebola outbreak.
Erica Schwartz, President Donald Trump’s nominee to lead the U.S. Centers for Disease Control and Prevention (CDC), is appearing before a Senate committee on Wednesday for a confirmation hearing that could bring stable leadership to the agency after months of turmoil. The hearing is a critical step for the CDC, which has lacked a confirmed director for nearly all of Trump's second term, according to a Reuters report.
The Confirmation Process
Schwartz, who previously served as deputy surgeon general in Trump's first term, will face questions from the Senate Committee on Health, Education, Labor and Pensions. The hearing, led by Republican Senator and physician Bill Cassidy, is the first for a permanent CDC director since Susan Monarez was confirmed and subsequently fired last year.
Senator Cassidy called Schwartz "very impressive" following a meeting last month, signaling potential support. The committee will also hold a hearing for Sean Kaufman, Trump’s nominee for assistant secretary for preparedness and response, whose past comments questioning vaccines have drawn scrutiny.
A History of Leadership Instability
The CDC has faced significant leadership challenges. The agency's last confirmed director, Susan Monarez, was dismissed less than a month into her tenure after reported clashes with Health Secretary Robert F. Kennedy Jr. on vaccine policy.
AdPrior to that, in March 2025, the administration withdrew its first nominee for the role, former Congressman Dave Weldon, just hours before his scheduled hearing after it became clear he lacked sufficient votes for confirmation. In contrast, Schwartz, a board-certified preventive medicine physician with no public record of opposing vaccines, is viewed as a more conventional nominee.
Pressing Public Health Crises
If confirmed, Schwartz will inherit an agency confronting several major public health emergencies. Key challenges include:
- A resurgence of measles, with U.S. cases in the current year on track to surpass 2025's total, which was the highest since the disease was declared eliminated in 2000.
- An international Ebola outbreak in the Democratic Republic of Congo and Uganda, which has prompted the CDC to activate its highest level of emergency response.
- Eroding public confidence in vaccines, which officials cite as a driver of falling childhood immunization rates.
Read next
More on Stocks
Apple's Tim Cook Views Australia's Social Media Curbs as 'World-Leading,' PM Albanese Says
Apple Executive Chair Tim Cook praised Australia's pioneering online safety measures as "world-leading," according to Prime Minister Anthony Albanese following a meeting at the tech giant's California headquarters.

Venezuela's Interim Government Signs Energy MOU with TotalEnergies
Venezuela's interim government signed a memorandum of understanding with French energy major TotalEnergies, the latest in a series of deals aimed at attracting foreign investment back into the nation's vast oil sector.

Huawei Unveils Advanced Power and Cooling Solutions for AI Data Centers
Huawei has launched a new suite of energy infrastructure and thermal management products for AI data centers, signaling a strategic shift towards integrated power storage and intelligent liquid cooling systems to meet the demands of high-density computing.

Shenzhen-Listed Jingxin Pharmaceutical Refiles for Hong Kong IPO
Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ) has resubmitted its application for a main board listing on the Hong Kong Stock Exchange, aiming to secure a dual listing to access international capital. The company specializes in drugs for central nervous system and cardiovascular diseases.